The drug delivery field at the inflection point: Time to fight its way out of the egg

[1]  William,et al.  Napoleon's Glance: The Secret Of Strategy (Nation Books) By William Duggan , 2019 .

[2]  A. Ghanem,et al.  Doctor average, good and excellent Mozart of Science , 2018 .

[3]  Raida Al-Kassas,et al.  Nanosizing techniques for improving bioavailability of drugs , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Rogério Gaspar,et al.  Rational design of nanoparticles towards targeting antigen‐presenting cells and improved T cell priming , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Randall D. Law.  Tyrants: A History of Power, Injustice, & Terror , 2017 .

[6]  Greg Satell.  Mapping Innovation: A Playbook for Navigating a Disruptive Age , 2017 .

[7]  Xiaoyuan Chen,et al.  Rethinking cancer nanotheranostics. , 2017, Nature reviews. Materials.

[8]  Celia N. Cruz,et al.  The evolving landscape of drug products containing nanomaterials in the United States. , 2017, Nature nanotechnology.

[9]  Ajay E. Kuriyan,et al.  Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. , 2017, The New England journal of medicine.

[10]  M. Gibson.  Pharmaceutical preformulation and formulation , 2017 .

[11]  Thomas Boraud,et al.  Poor replication validity of biomedical association studies reported by newspapers , 2017, PloS one.

[12]  Olivia Fox Cabane,et al.  The Net and the Butterfly , 2017 .

[13]  Samir Mitragotri,et al.  Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond. , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[14]  David A Jaffray,et al.  Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements☆ , 2017, Advanced drug delivery reviews.

[15]  Tian Zhang,et al.  Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[16]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[17]  F. Danhier,et al.  To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Kinam Park,et al.  Drug delivery of the future: Chasing the invisible gorilla. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[19]  J. Ioannidis,et al.  What Happens When Underperforming Big Ideas in Research Become Entrenched? , 2016, JAMA.

[20]  Mihail C. Roco,et al.  Nano on reflection. , 2016, Nature nanotechnology.

[21]  Gerard Pasterkamp,et al.  Lost in the citation valley , 2016, Nature Biotechnology.

[22]  M. Gittelman.  The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery , 2016 .

[23]  Scott E. McNeil,et al.  Evaluation of nanomedicines: stick to the basics , 2016, Nature Reviews Materials.

[24]  A. J. Tavares,et al.  Reply to “Evaluation of nanomedicines: stick to the basics” , 2016, Nature Reviews Materials.

[25]  S. Alzghari,et al.  Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Michael Torrice,et al.  Does Nanomedicine Have a Delivery Problem? , 2016, ACS central science.

[27]  Melonie P. Heron,et al.  Deaths: Leading Causes for 2014. , 2016, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[28]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[29]  Robert H. Frank,et al.  Success and Luck: Good Fortune and the Myth of Meritocracy , 2016 .

[30]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[31]  Mark Manson.  The subtle art of not giving a fuck : a counterintuitive approach to living a good life , 2016 .

[32]  Kinam Park,et al.  Historical Introduction to the Field of Controlled Drug Delivery , 2016 .

[33]  Ronald J. Daniels,et al.  A generation at risk: Young investigators and the future of the biomedical workforce , 2015, Proceedings of the National Academy of Sciences.

[34]  Joseph W. Nichols,et al.  EPR: Evidence and fallacy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Tracy K. Pettinger,et al.  Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.

[36]  L. A. Hill,et al.  Collective Genius: The Art and Practice of Leading Innovation , 2014 .

[37]  J. Verweij,et al.  Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles , 2001, Cancer Chemotherapy and Pharmacology.

[38]  G. Pillai,et al.  Nanomedicines for Cancer Therapy : An Update of FDA Approved and Those under Various Stages of Development , 2014 .

[39]  Seiji Miura,et al.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[40]  Kinam Park,et al.  Facing the truth about nanotechnology in drug delivery. , 2013, ACS nano.

[41]  Luc de Brabandere,et al.  Thinking in New Boxes: A New Paradigm for Business Creativity , 2013 .

[42]  Kinam Park,et al.  Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. , 2013, International journal of pharmaceutics.

[43]  Cfp,et al.  The Invisible Gorilla in the Room , 2013 .

[44]  Arthur G Erdman,et al.  The big picture on nanomedicine: the state of investigational and approved nanomedicine products. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[45]  V. Venditto,et al.  Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.

[46]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[47]  T. Hartung.  Look back in anger - what clinical studies tell us about preclinical work. , 2013, ALTEX.

[48]  Katherine Bourzac,et al.  Nanotechnology: Carrying drugs , 2012, Nature.

[49]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[50]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Tina Lynn Seelig,et al.  inGenius: A Crash Course on Creativity , 2012 .

[52]  Tim Harford,et al.  Adapt: Why Success Always Starts with Failure , 2011 .

[53]  D. Watts.  Everything Is Obvious: *Once You Know the Answer , 2011 .

[54]  Albert Einstein,et al.  The Ultimate Quotable Einstein , 2010 .

[55]  H. Wen,et al.  Oral controlled release formulation design and drug delivery : theory to practice , 2010 .

[56]  Ping I. Lee,et al.  Evolution of Oral Controlled Release Dosage Forms , 2010 .

[57]  E. R. Cooper,et al.  Nanoparticles: A personal experience for formulating poorly water soluble drugs. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[58]  Mohan Srinivasarao,et al.  Colloidal dispersion of gold nanorods: Historical background, optical properties, seed-mediated synthesis, shape separation and self-assembly , 2009 .

[59]  Allan S. Hoffman,et al.  The origins and evolution of "controlled" drug delivery systems. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[60]  Peter Cummins.  The Construction of Emotion , 2008 .

[61]  J. Brooks.  Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .

[62]  David Thompson.  Michael Faraday's recognition of ruby gold: the birth of modern nanotechnology , 2007 .

[63]  Joachim Schummer.  The global institutionalization of nanotechnology research: A bibliometric approach to the assessment of science policy , 2007, Scientometrics.

[64]  J. Ioannidis.  Contradicted and initially stronger effects in highly cited clinical research. , 2005, JAMA.

[65]  T. Abribat,et al.  The rise and rise of drug delivery , 2005, Nature Reviews Drug Discovery.

[66]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[67]  J. Verweij,et al.  Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins , 2003, Clinical pharmacology and therapeutics.

[68]  J. Verweij,et al.  Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel , 2002, Anti-cancer drugs.

[69]  H. Williams.  New treatments for atopic dermatitis , 2002, BMJ : British Medical Journal.

[70]  Mark Gibson,et al.  Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form , 2001 .

[71]  W. Brown.  What about the Mozarts of science? , 2001, Redox report : communications in free radical research.

[72]  R. Zander,et al.  The Art of Possibility , 2000 .

[73]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.

[74]  Andrew S. Grove,et al.  Only the Paranoid Survive: How to Exploit the Crisis Points that Challenge Every Company and Career , 1996 .

[75]  D. Kessel.  PROPERTIES OF CREMOPHOR EL MICELLES PROBED BY FLUORESCENCE , 1992, Photochemistry and photobiology.

[76]  M. Sharratt.  The Galileo affair: A documentary history , 1990 .

[77]  J. Weinstein,et al.  Liposomes as drug carriers in cancer chemotherapy. , 1984, Pharmacology & therapeutics.

[78]  R. W. Baldwin,et al.  Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro , 1983 .

[79]  Patrick Couvreur,et al.  Pharmacokinetics and Distribution of a Biodegradable Drug-carrier , 1983 .

[80]  H. Ellens.  Liposomes as drug carriers in cancer chemotherapy , 1982 .

[81]  J. Kreuter,et al.  In vitro studies of poly(methyl methacrylate) adjuvants. , 1976, Journal of pharmaceutical sciences.

[82]  P. Kratochvíl,et al.  Block and graft copolymer micelles in solution , 1976 .

[83]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[84]  Peter F. Drucker,et al.  Managing for business effectiveness. , 1963 .